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Human mucosal-associated invariant T (MAIT) cells are an important T cell subset that 
are enriched in tissues and possess potent effector functions. Typically such cells are 
marked by their expression of Vα7.2-Jα33/Jα20/Jα12 T cell receptors, and functionally 
they are major histocompatibility complex class I-related protein 1 (MR1)-restricted, 
responding to bacterially derived riboflavin synthesis intermediates. MAIT cells are con-
tained within the CD161++ Vα7.2+ T cell population, the majority of which express the 
CD8 receptor (CD8+), while a smaller fraction expresses neither CD8 or CD4 coreceptor 
(double negative; DN) and a further minority are CD4+. Whether these cells have distinct 
homing patterns, phenotype and functions have not been examined in detail. We used a 
combination of phenotypic staining and functional assays to address the similarities and 
differences between these CD161++ Vα7.2+ T cell subsets. We find that most features 
are shared between CD8+ and DN CD161++ Vα7.2+ T cells, with a small but detectable 
role evident for CD8 binding in tuning functional responsiveness. By contrast, the CD4+ 
CD161++ Vα7.2+ T cell population, although showing MR1-dependent responsiveness 
to bacterial stimuli, display reduced T helper 1 effector functions, including cytolytic 
machinery, while retaining the capacity to secrete interleukin-4 (IL-4) and IL-13. This 
was consistent with underlying changes in transcription factor (TF) expression. Although 
we found that only a proportion of CD4+ CD161++ Vα7.2+ T  cells stained for the 
MR1-tetramer, explaining some of the heterogeneity of CD4+ CD161++ Vα7.2+ T cells, 
these differences in TF expression were shared with CD4+ CD161++ MR1-tetramer+ 
cells. These data reveal the functional diversity of human CD161++ Vα7.2+ T cells and 
indicate potentially distinct roles for the different subsets in vivo.
Keywords: mucosal-associated invariant T cells, innate-like T cells, Mhc class i-related protein 1-tetramer, Mhc 
class i-related protein 1, subsets, transcription factors, cD8 coreceptor
inTrODUcTiOn
Mucosal-associated invariant T (MAIT) cells are a population of innate T lymphocytes expressing 
the semi-invariant T cell receptor (TCR), classically consisting of Vα7.2-Jα33/Jα12/Jα20 in humans, 
and Vα19-Jα33 in mice, which are paired with a restricted Vβ repertoire (1–4). This TCR allows 
them to recognize riboflavin metabolite-based antigens and folate derivatives presented by the highly 
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conserved, monomorphic major histocompatibility complex 
(MHC) class I-related protein 1 (MR1) (5–7).
The identification of MAIT  cells using MR1-tetramers 
has clearly demonstrated that MAIT  cells can be divided into 
CD8+, CD4+, and CD8− CD4− (double negative; DN) subsets 
(4, 5, 8). The frequency of each subset and their distribution var-
ies between mammalian species and is also influenced by age and 
tissue location. In ruminants and Vα19-Jα33 TCR-transgenic 
mice, the majority of the MAIT cells are DN (9, 10), whereas 
within humans they are predominantly CD8+ (4, 11, 12). 
Furthermore, while more than half of these CD8+ MAIT cells 
express the CD8αα homodimer in adults, MAIT cells in second 
trimester fetal thymi express the CD8αβ heterodimer, with 
CD8αα expression associated with the acquisition of a memory 
phenotype (12, 13). The frequency of these CD8+ MAIT cells 
in the periphery falls with age (14–16). Furthermore, a recent 
study using MR1-tetramers in wild-type mice has demonstrated 
that, similar to humans, certain laboratory strains of mice have 
a larger fraction of MAIT cells that are CD8+ (8). Furthermore, 
the distribution of murine MAIT  cell subsets differs between 
tissues, with an enrichment of CD4+ MAIT cells in lymph nodes 
(8). Altogether, these reports highlight the heterogeneity of the 
frequency and distribution of MAIT cell subsets. However, the 
functional relationship between the different subsets, especially 
in humans, is poorly understood.
Mucosal-associated invariant T  cells share many develop-
mental and functional features with invariant natural killer 
(NK) T (iNKT) cells. Similar to MAIT cells, CD1d-restricted 
iNKT cells consist of CD4+ and CD4− subsets (17–19), where 
CD4− iNKT cells secrete T helper 1 (Th1) cytokines, as well as 
interleukin-17 (IL-17), while CD4+ iNKT cells are the domi-
nant producers of Th2 and immunoregulatory cytokines, such 
as interleukin-4 (IL-4), IL-10, and IL-13 (18, 20, 21). The bal-
ance between these subsets is thought to be key in determining 
the protective or pathological role of iNKT cells in disease (22). 
For example, while CD4+ iNKT cells protected non-obese dia-
betic mice from developing type 1 diabetes, CD4− iNKT cells 
secreting IL-17 exacerbated the disease (22). Furthermore, the 
cytolytic and Th1 cytokine-producing CD4− iNKT cells are the 
main effector population in tumor rejection (23) and control of 
microbial infections (24, 25). Most of the previous MAIT cell 
studies have focused on the dominant population of MAIT cells 
in mice (DN) and humans (CD8+). Therefore, whether the dif-
ferent subsets have the potential to play a different function in 
disease remains unknown. Furthermore, whether differential 
expression of transcription factors (TFs) may account for the 
differences in MAIT cell subsets has not been fully investigated.
In humans, MAIT cells can be identified as cells expressing 
the C-type lectin-like receptor CD161 at a high level together 
with the Vα7.2 TCRα chain (4, 11, 26). These cells have previ-
ously been shown to overlap with cells stained with the MR1-
tetramer, particularly in the CD8+ and DN subsets (4, 27). 
High expression of CD161 is a feature of innate-like T cells that 
have the ability to respond to innate cytokines and share a tran-
scriptional signature, regardless of the specificity of their TCR 
(28), and CD161++ Vα7.2+ T cells—the majority of which are 
MAIT cells—are contained within this family of T cells. In this 
study, we have examined the frequency of CD161++ Vα7.2+ 
T cell subsets in human peripheral blood, liver, and bone marrow 
(BM), and performed a detailed analysis of the overlapping and 
distinct phenotypic and functional features of each.
MaTerials anD MeThODs
Blood and Tissue samples
Whole blood was obtained from leukocyte cones (NHS Blood 
and Transplant); 2-year-old donors (obtained from a cohort 
of Swedish infants) (29); or umbilical cord blood samples 
(Stem Cell Services, NHS Blood and Transplant); or healthy 
laboratory volunteers. Intrahepatic lymphocytes were collected 
from donors after portal flush using cold preservation solu-
tion following removal of the right lobe of the donor’s livers 
(non-pathological liver grafts preceding liver transplantation; 
Duke-NUS Graduate Medical School, Singapore) as previously 
described (30). The BM samples were obtained from routine 
hip joint operations (Newcastle University). Samples were 
filtered (40 µm), washed with phosphate buffered saline (PBS) 
and homogenized. Mononuclear cells from the above blood and 
tissues were isolated by standard density gradient centrifugation 
(Lymphoprep™ Axis Shield Diagnostics). Blood and tissue 
samples were cryopreserved and thawed before use. Adult and 
cord blood samples were collected after ethical approval by the 
Central Office for Research Ethics Committees (COREC, local 
research ethics committee Oxford), reference number COREC 
04.OXA.010. Liver samples were collected after ethic approval 
of the Asian American Liver Center Ethic committee (Glean 
Eagle Hospital, Singapore), reference number PIEC/2012/037. 
For samples used for genomic DNA (gDNA) analysis, samples 
were collected after ethical approval by the University of Otago 
Human Ethics Committee (Health), reference number H14/046. 
All patients from the studies above provided their informed writ-
ten consent. The collection of blood samples for the 2-year-old 
study cohort was approved by the Human Ethics Committee 
at Huddinge University Hospital, Stockholm, reference code 
75/97, 331/02, and the parents provided their informed verbal 
consent. No written documentation of the participants informed 
approval was required, which was agreed to by the Human Ethics 
Committee and was according to the regulations at the time of 
the initiation of the study.
Abbreviations: MAIT, mucosal-associated invariant T; DN, double-negative 
(CD4− CD8−); DP, double-positive (CD4+ CD8+); TCR, T cell receptor; MHC, 
major histocompatibility complex; MR1, MHC class I-related protein 1; Gr, 
Granzyme; Escherichia coli, E. coli; iNKT, CD1d-restricted invariant natural killer 
T cells; NK, natural killer cells; IHL, intrahepatic lymphocytes; BM, bone marrow; 
PLZF, promyelocytic leukemia zinc finger protein; RORγt, RAR-related orphan 
receptor γ t; 5-OP-RU, 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil; 
6-FP, 6-formyl pterin; β2M, β-2-microglobulin; Foxp3, forkhead box P3; gDNA, 
genomic DNA; ThPOK, Th-inducing POK; gMFI, geometric mean fluorescence 
intensity; T helper, Th; Eomes, eomesodermin; T-bet, T-box expressed in T cells; 
SEM, standard error of the mean; TF, transcription factor; PBS, phosphate buffered 
saline; PBMCs, peripheral blood mononuclear cells; FCS, fetal calf serum; PMA, 
phorbol 12-myristate 13-acetate; IL-4, interleukin-4; IFNγ, interferon-γ; TGF-β, 
transforming growth factor-β; MIP-1β, macrophage inflammatory protein-1β; 
TNFα, tumor necrosis factor-α; Yr., Year; FACS, fluorescence-activated cell sorted.
FigUre 1 | Frequency of CD161++ Vα7.2+ T cell subsets in human blood and tissue. (a) Gating strategy used to identify CD161++ Vα7.2+ T cells and their 
subsets in this study. (B) Frequencies of adult peripheral blood CD161++ Vα7.2+ T cells that are CD4+, CD8+ or CD4− CD8− (double negative; DN) (mean ± SEM) 
(n = 32; pooled from four independent experiments). ****P < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test. (c,D) Representative staining 
showing the expression of coreceptors on CD161++ Vα7.2+ T cells from (c) an intrahepatic lymphocyte sample (IHL) and (D) bone marrow (BM) sample.  
(e) Frequencies of CD8+ (red), DN (blue) or CD4+ (green) cells within total CD161++ Vα7.2+ T cells in the indicated tissues. N = 32 (adult blood), 28 (2-year-old 
blood), 3 (cord blood), 3 (liver), and 4 (BM). ***P < 0.001 by two-way ANOVA with Dunnett’s multiple comparisons test compared to adult peripheral blood. All other 
comparisons were non-significant. (F–i) The frequency of CD161++ Vα7.2+ T cells within (F) total T cells, (g) CD8+ T cells, (h) DN T cells, or (i) CD4+ T cells in the 
indicated tissues. N = 32 (adult blood), 28 (2-year-old blood), 3 (cord blood), 3 (liver), 4 (BM). Bars indicate mean ± SEM. Yr, year. ****P < 0.0001, ***P < 0.001, 
*P < 0.05 by two-way ANOVA with Dunnett’s multiple comparisons test compared to adult peripheral blood. All other comparisons were non-significant.
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Flow cytometry
The gating strategy used in this study is detailed in Figure 1A. 
For immunofluorescence staining, dead cells were excluded 
with the Live/Dead Fixable near-IR dead-cell stain (Invitrogen). 
For internal staining, cells were fixed with 1% formaldehyde 
(Sigma Aldrich) and permeabilized with permeabilization 
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buffer (eBioscience). For TF staining, cells were stained with 
the Foxp3/TF Staining Buffer Set (eBioscience) according to 
the manufacturers’ protocol. Antibodies used were as follows: 
anti-CD3 PE-Cy7 or eFluor 450, anti-CD8α eFluor 450 or 
PerCP-Cy5.5, anti-CD4 PE-Cy7, anti-T-bet PE, anti-Eomes 
eFluor 660, anti-Eomes FITC, anti-CD69 FITC, anti-IL-17A 
PE, anti-IL-18Rα PE, anti-CXCR4 PE, and anti-CD94 FITC 
(eBioscience); anti-CD4 VioGreen, anti-CD8 VioGreen, anti-
CD161 PE or APC, anti-IFNγ FITC, anti-CD127 FITC, anti-
CD56 APC, anti-CD45 FITC, and anti-TCR γδ T APC-Vio770 
(Miltenyi Biotec); anti-promyelocytic leukemia zinc finger 
(PLZF) APC, anti-macrophage inflammatory protein-1β (MIP-
1β) PE, anti-CCR9 PE, and anti-GrA FITC (R&D Systems); 
anti-CD4 Brilliant Violet 605, anti-CD8 Alexa Fluor 700, anti-
CCR7 PE-Cy7, anti-CD56 Brilliant Violet 421, anti-RAR-related 
orphan receptor γ t (RORγt) PE, anti-CCR6 PerCP-Cy5.5, 
anti-CCR3 PE, anti-CXCR3 PE, and anti-CD38 FITC (BD 
Biosciences); anti-CD161 Pacific Blue, anti-Vα7.2 FITC, APC, 
PE, or PE-Cy7, anti-CD3 PerCP-Cy5.5, anti-TNFα PE-Cy7, anti-
Perforin Pacific Blue, anti-IL-4 APC, anti-IL-13 PerCP-Cy5.5, 
anti-Th-inducing POK (ThPOK) PE, anti-CD45RO PE-Cy7, 
anti-CD45RA PerCP-Cy5.5, anti-CD62L PE-Cy7, anti-CLA1 
Pacific Blue, anti-CCR2 PerCP-Cy5.5, anti-CCR4 PerCP-Cy5.5, 
anti-CCR5 PerCP-Cy5.5, anti-CCR7 PerCP-Cy5.5, anti-CD25 
PE, and anti-CX3CR1 FITC (Biolegend); anti-CD3 Pacific 
Orange and anti-Granzyme B (GrB) APC (Invitrogen); anti-
Granzyme K FITC (Immunotools); and anti-NKG2A (Beckman 
Coulter).
For MR1-tetramer staining, peripheral blood mono-
nuclear cells (PBMCs) were treated with TruStain FcX Fc 
Receptor Blocking solution (Biolegend) at 37°C for 20  min, 
washed with PBS and then stained with antibodies against 
surface markers and Live/Dead Fixable near-IR dead-cell stain 
(Invitrogen) in PBS. Cells were then washed and stained with 
the 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil (5-OP-
RU) MR1-tetramer-PE (gifted by Professor James McCluskey 
or obtained from the NIH Tetramer Core Facility) or Vα7.2-PE 
antibody for 40 min at room temperature in PBS+ 2% fetal calf 
serum (FCS). Following further washes, cells were fixed and 
permeabilized using the Foxp3/TF Staining Buffer Set (eBiosci-
ence) following the manufacturer’s instructions (eBioscience), 
followed by staining with antibodies against intracellular TFs. 
Where indicated, tetramer+ cells were positively enriched using 
PE Microbeads (Miltenyi Biotech) before staining.
In Vitro stimulation of cD161++ Vα7.2+  
T cells
THP1 cells (ECACC, UK) were incubated overnight with 
paraformaldehyde (PFA)-fixed Escherichia coli (E. coli; DH5α, 
Invitrogen) at a ratio of 25 bacteria per cell, or a sterility control. 
THP1 cells were washed extensively, and PBMCs, intrahepatic 
lymphocytes, enriched CD8+ T  cells, or sorted CD161++ 
Vα7.2+ T cells were added to the THP1 cells for a 5-h stimula-
tion. Brefeldin A (eBioscience) was added for the final 4 h of the 
stimulation. Alternatively, for the assessment of degranulation, 
anti-CD107a-PE-Cy7 (BioLegend) was added from the start 
of the stimulation. For the assessment of GrB and perforin 
upregulation, PBMCs were added to E. coli-treated THP1 cells 
for 24 h. MAIT cell apoptosis was detected by Annexin V surface 
staining (Miltenyi Biotec), in Annexin V binding buffer (Miltenyi 
Biotec) for 15 min. Staurosporine (Sigma Aldrich) was added as 
a positive control. Alternatively, MAIT cells were stimulated with 
IL-12+ IL-18 (both Miltenyi Biotech) at 50 ng/ml for 20 h, and 
brefeldin A (eBioscience) was added at 3 µg/ml for the final 4 h 
of the incubation. For blocking experiments, anti-MR1 antibody 
(gift from Professor Ted Hansen or from Biolegend), anti-IL-
12p40/70, anti-IL-18 antibody (both Miltenyi Biotech), or the 
appropriate isotype controls were added at 10 µg/ml. Anti-CD8α 
antibody (clone LT8; Novus Biologicals) was added at the indi-
cated concentrations.
culture of MaiT cells in Th2-skewing 
conditions
Peripheral blood mononuclear cells were cultured in RPMI-1640 
with 10% human AB serum + penicillin/streptomycin (all from 
Sigma Aldrich) with 100 ng/ml IL-4 (PreproTech Inc.) and 50 U/
ml IL-2 (Miltenyi Biotec) for 6  days, as previously described 
(31), before washing and stimulation with Phorbol 12-myristate 
13-acetate (PMA) and ionomycin (both 250  ng/ml; Sigma 
Aldrich) for 5 h. Brefeldin A (Sigma Aldrich) was added at 10 µg/
ml for the final 4 h of the stimulation.
il-12/il-18 stimulation of sorted 
cD161++ Vα7.2+ T cell subsets
Peripheral blood mononuclear cells obtained from leukocyte 
cones were stained with the following fluorochrome-labeled anti-
bodies; anti-CD8β PE (Beckman Coulter), anti-CD3 V500, anti-
CD8α PerCP, anti-CD4 PE-Cy7, anti-CD161 BV421, anti-Vα7.2 
FITC and Zombie Green Fixable Viability marker (Biolegend), 
and Fluorescence-activated cell sorted (FACS) (FACSFusion, 
BD Biosciences) into indicated MAIT cell subsets. After sorting 
cells were washed in PBS and incubated for 48 h in RPMI-1640 
(Sigma Aldrich) with 10% FCS + penicillin/streptomycin con-
taining IL-12 and IL-18 (both Miltenyi Biotech) at 50 ng/ml along 
with unsorted PBMCs as negative (unstimulated) and positive 
(stimulated with IL-12 and IL-18 or PMA/Ionomycin) controls. 
Supernatants were collected at 48  h and cytokine analysis was 
performed using the bead-based immunoassay LEGENDplex 
human Th17 panel (Biolegend) according to the manufacturer’s 
protocol and analysis performed using LEGENDplex data analy-
sis software (Biolegend).
Quantitative real-time Pcr
To isolate CD4+ CD161++ Vα7.2+ T  cells, CD4+ cells were 
initially positively selected from freshly isolated PBMCs with the 
CELLection™ Pan Mouse IgG Kit (Thermo Fisher Scientific), 
as per the manufacturer’s instructions. Vα7.2+ cells were then 
positively selected with anti-PE microbeads (Miltenyi Biotec) 
as per the manufacturer’s instructions. Cells were then stained 
and CD4+ CD161++ Vα7.2+ CD3+ cells sorted on a FACS Aria 
(BD Biosciences). CD8+ CD161++ Vα7.2+ CD3+ cells and 
CD161− Vα7.2− CD3+ cells were sorted directly from PBMC on 
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a FACS Aria (BD Biosciences). DNA was extracted from sorted 
cells using PureLink Genomic DNA Mini Kit (Life Technologies) 
as per the manufacturer’s instructions.
The real-time PCR was performed as previously described for 
on an Viia™ 7 Real-time PCR System (Applied Biosystems) using 
KAPA PROBE FAST qPCR Master Mix (2X) Universal Kit (Kapa 
Biosystems), except for the MAIT cell assay (Vα7.2-Jα33/12/20) 
the following primers and probes were used: Vα7.2 forward primer 
(TCCTTAGTCGGTCTAAAGGGTACAG), 1  µM; Jα33 reverse 
primer (CCAGCGCCCCAGATTAA), 200  nM; Jα12 reverse 
primer (GTCCCACTCCCGAAGATCAATTT) 400  nM; Jα20 
reverse primer (TGTGGTTCCGGCTCCAAAG), 400 nM; Vα7.2 
probe (6-FAM/AGGTTGCTC/ZEN/CACAGGTAGCTCTAGG/
Iowa Black FQ), 400 nM. The efficiency of the Vα7.2-Jα33/12/20 
and β-2-microglobulin (β2M) assays were 92.5 and 102.3%, 
respectively.
Data acquisition and statistical analysis
Data were collected on the MACSQuant Analyzer (Miltenyi 
Biotech) and were analyzed using FlowJo v9.8 (TreeStar). All 
graphs and statistical analyses were completed using GraphPad 
Prism software Version 6. All data are presented as means with 
SEM, unless otherwise indicated.
resUlTs
Frequencies of cD161++ Vα7.2+ T cell 
subsets in healthy Blood and Tissue
Mucosal-associated invariant T  cells have been previously 
described to be contained within the CD161++ Vα7.2+ T cell 
population (4, 11). Gating on all CD3+ CD161++ Vα7.2+ T cells 
in healthy adult peripheral blood, the majority of CD161++ 
Vα7.2+ T  cells were found to be either CD8+ (82.9 ±  1.5%) 
or DN (12.1  ±  1.1%), while CD4+ cells only accounted for 
1.9 ± 0.3% of total CD161++ Vα7.2+ T cells in adult peripheral 
blood (Figures 1A,B), in line with previous studies (32, 33).
Next, coreceptor usage of CD161++ Vα7.2+ T cells in BM and 
liver was compared to that of blood from cord blood, 2-year-old, 
and adult donors. This revealed that the distribution of CD161++ 
Vα7.2+ T cell subsets within intrahepatic lymphocytes [intrahe-
patic lymphocyte sample (IHL); Figure 1C] and in the memory 
T cell fraction of BM (Figure 1D) is similar to peripheral blood, 
where the CD8+ CD161++ Vα7.2+ T  cell population con-
stitutes the majority of CD161++ Vα7.2+ T cells (Figure 1E). 
Interestingly, the expression of the CD8 coreceptor by blood 
CD161++ Vα7.2+ T cells increased with age, when comparing 
cord, 2-year-old, and adult peripheral blood.
Looking at the frequency of these cells within T cell populations, 
CD161++ Vα7.2+ T cells accounted for a mean of 2% of adult 
circulating T cells (Figure 1F), comparable to previous reports 
(27, 34). Within different T cell subsets in adult peripheral blood, 
CD161++ Vα7.2+ T cells were found at an average frequency of 
7% within CD8+, 11% within DN, and 0.05% of CD4+ T cells 
(Figures 1G–I). The frequency of CD161++ Vα7.2+ cells within 
T cells increased with age, as previously described. Interestingly, 
this increase occurred within CD4+ T  cells as well as within 
CD8+ and DN T cells, suggesting that CD161++Vα7.2+ T cells 
expand with age regardless of coreceptor expression.
cell surface Phenotype heterogeneity of 
human cD161++ Vα7.2+ T cells
The previously reported enrichment of CD4+ MAIT cells in lymph 
nodes in mice (8) suggests that different MAIT  cell subsets may 
traffic to different tissues and, therefore, the expression of chemokine 
receptors was compared. Blood CD161++ Vα7.2+ T  cell subsets 
were uniformly high for CCR2, CCR5, and CCR6, and had low or 
little expression of CCR3, CXCR3, and CXCR4 (Figures 2A,B), as 
previously reported in CD8+ MAIT cells (11). Although some differ-
ences in expression were seen for CCR2, CCR5, and CCR6, the largest 
difference between the subsets was the expression of CCR4 and CCR7. 
A small proportion (25%) of CD4+ CD161++ Vα7.2+ T cells were 
found to express CCR4, which was significantly higher than the CD8+ 
and DN cells. CCR7 expression was similarly only found on a minority 
(27%) of CD4+ CD161++ Vα7.2+ T cells, while completely absent on 
CD8+ and DN subsets.
Next, we investigated whether other cell surface markers 
expressed by CD8+ CD161++ Vα7.2+ T cells were differentially 
expressed in CD4+ and DN CD161++ Vα7.2+ T cells (Figure 2C). 
First, a low frequency of CD8+ and DN CD161++ Vα7.2+ 
T  cells expressed the early activation marker CD69, suggesting 
a level of constitutive activation during circulation. However, the 
expression of CD69 on CD4+ CD161++ Vα7.2+ T cells was vir-
tually absent. By contrast, CD25 was exclusively found on CD4+ 
CD161++ Vα7.2+ T cells. Of note, this CD25+ CD4+ CD161++ 
Vα7.2+ T cell population lacked expression of forkhead box P3 
(Foxp3) and was unable to produce transforming growth factor β 
(data not shown). In addition, the cytokine receptors IL-18R and 
CD127 were highly expressed in all subsets of CD161++ Vα7.2+ 
T cells, albeit at a slightly lower frequency in CD4+ CD161++ 
Vα7.2+ T  cells. Lastly, NK  cell receptors CD56, NKG2A, and 
CD94 were consistently expressed on CD8+ and DN CD161++ 
Vα7.2+ T cells, but CD4+ CD161++ Vα7.2+ T cells lacked their 
expression, suggesting their lack of cytotoxic potential. Significant 
phenotypic differences between CD161++ Vα7.2+ T cell subsets 
are summarized in Table S1 in Supplementary Material.
cD4+ cD161++ Vα7.2+ T cells have 
reduced eomes expression and low 
cytotoxic Potential
Next we looked at the differences in TF expression in CD161++ 
Vα7.2+ T  cell subsets. All three subsets of blood CD161++ 
Vα7.2+ T cells expressed high levels of RORγt and were found 
to be T-betlow (T-box expressed in T  cells; Figures  3A–C), as 
previously described (35), although CD4+ CD161++ Vα7.2+ 
T cells had a slightly lower frequency of cells expressing RORγt 
compared to CD4− CD161++ Vα7.2+ T  cells. In addition, 
CD8+ MAIT cells have also been shown to express the master 
regulator of innate-like T cells, PLZF, at high levels (11, 28). We 
found that all three subsets uniformly expressed PLZF, but the 
frequency of cells expressing PLZF was slightly, but significantly 
lower in the CD4+ CD161++ Vα7.2+ T cells compared to the 
CD8+ CD161++ Vα7.2+ T cells (Figures 3A,B).
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FigUre 2 | Continued  
Cell surface phenotype heterogeneity of human CD161++ Vα7.2+ T cells. (a) Percentage of CD8+, double negative (DN), and CD4+ CD161++ Vα7.2+ T cells 
expressing the indicated chemokine receptors. Bars indicate mean ± SEM. ****P < 0.0001, ***P < 0.001, *P < 0.05 by two-way repeated measures ANOVA with 
Dunnett’s multiple comparisons test, compared to CD8+ CD161++ Vα7.2+ T cells. All other comparisons were not significant (n = 5–15; data pooled from 
independent experiments with biological replicates of 5). (B) Representative flow cytometry plots gated on total CD8+ (top row), DN (second row), CD4+ (third row) 
T cells showing expression of indicated chemokine receptors. Blue = CD161++ Vα7.2+ T cells; red = bulk T cells. Bottom row shows histograms for cells gated on 
CD8+, DN, or CD4+ CD161++ Vα7.2+ T cells. (c) Percentage of CD8+, DN, or CD4+ CD161++ Vα7.2+ T cells expressing the indicated surface receptors. Bars 
indicate mean ± SEM. ****P < 0.0001, ***P < 0.001, *P < 0.01 by two-way repeated measures ANOVA with Dunnett’s multiple comparisons test, compared to 
CD8+ CD161++ Vα7.2+ T cells. All other comparisons were not significant (n = 5–13).
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Next, the expression of ThPOK was examined, a TF associ-
ated with CD4 lineage commitment during thymic development 
(36), which also suppresses RORγt expression in iNKT  cells 
(37). We found that all three subsets of CD161++ Vα7.2+ 
T  cells expressed ThPOK (Figures  3A,B). Interestingly, when 
comparing the geometric mean fluorescence intensity of ThPOK 
expressed by CD161++ Vα7.2+ T cells to conventional CD4+, 
CD8+, or DN T cells (Vα7.2−), CD161++ Vα7.2+ T cells were 
found to consistently express higher levels of ThPOK compared 
to conventional CD8+ and DN T cells, while expressing lower 
levels compared to conventional CD4+ T cells (Figures S1A,B 
in Supplementary Material), showing that CD161++ Vα7.2+ 
T cells are ThPOKlow.
Lastly, we found that CD4+ CD161++ Vα7.2+ T  cells 
expressed significantly less Eomesodermin (Eomes) compared 
to CD8+ and DN CD161++ Vα7.2+ T  cells in frequency 
(Figure 3A), with an average of 50% of CD4+ CD161++ Vα7.2+ 
T cells expressing Eomes compared to CD8+ and DN CD161++ 
Vα7.2+ T cells, in which the majority of cells expressed Eomes. 
Previously, we have shown that CD8+ CD161++ Vα7.2+ T cells 
express granzyme A (GrA), GrK, and low levels of perforin at 
resting conditions (38). The greatly lower expression of Eomes 
by CD4+ CD161++ Vα7.2+ T  cells suggests that these cells 
may have low cytotoxic potential. Indeed, we found that DN 
CD161++ Vα7.2+ T cells expressed GrA, GrK, and perforin at 
comparable frequencies to CD8+ cells, but significantly reduced 
frequencies of CD4+ CD161++ Vα7.2+ T cells expressed GrA, 
GrK, and perforin compared to CD8+ cells (Figures 3D–G). All 
subsets expressed little GrB at resting conditions.
CD8+ MAIT  cells can rapidly upregulate GrB and perforin 
following bacterial stimulation, which arms these cells with the 
ability to efficiently kill target cells (35, 38). To investigate whether 
CD4+ CD161++ Vα7.2+ T cells can become killers, CD161++ 
Vα7.2+ T cells were stimulated with E. coli-treated THP1 cells for 
24 h and GrB and perforin expression was analyzed. As shown 
in Figures 3H,I, the increase in the fraction of CD4+ CD161++ 
Vα7.2+ T cells expressing GrB was significantly lower compared 
to CD8+ CD161++ Vα7.2+ T cells. There was no significant dif-
ference between all subsets in their ability to upregulate perforin 
in response to bacterial stimulation.
cD8+ and Dn cD161++ Vα7.2+ T cells 
have a higher capacity to secrete Th1 
cytokines
Next, to determine the functional differences between the three 
CD161++ Vα7.2+ T  cell subsets, E. coli-treated THP1 cells 
were used to probe the MR1-dependent activation of CD161++ 
Vα7.2+ T cells. THP1 cells were cultured with PFA-fixed E. coli 
overnight before washing and co-culturing with PBMCs for 5 h. 
We did not observe a significant difference in the expression of 
the CD8 or CD4 coreceptors or proportions of CD8, DN, and 
CD4+ CD161++ Vα7.2+ T  cells following E. coli stimulation 
due to change in coreceptor expression (Figures S2A–C in 
Supplementary Material) in control experiments. There was a 
clear production of interferon-γ (IFNγ) from all three subsets of 
CD161++ Vα7.2+ T cells after stimulation with E. coli-treated 
THP1 cells, which was completely blocked by the addition of 
an anti-MR1 blocking antibody (Figures 4A,B), consistent with 
previous work in this time frame (39). IL-17 was expressed by 
all CD161++ Vα7.2+ T cell subsets and its expression was also 
completely MR1 dependent (Figure 4C).
Using this MR1-dependent model of MAIT  cell activation, 
the frequency of cytokine-producing cells within each subset 
was further compared. There was no difference in the frequency 
of CD8+ and DN CD161++ Vα7.2+ T  cells producing IFNγ, 
but the frequency of CD4+ CD161++ Vα7.2+ T cells producing 
IFNγ and tumor necrosis factor-α (TNFα) was significantly lower 
(Figures 4D,E). Importantly, while similar frequencies of CD8+ 
and DN CD161++ Vα7.2+ T  cells were able to degranulate 
(Figure  4F), there was a complete lack of degranulation from 
CD4+ CD161++ Vα7.2+ T cells.
In addition, as MAIT cells can also be activated in an MR1-
independent manner through cytokines (39), PBMCs were 
stimulated overnight with IL-12 + IL-18, and the expression of 
IFNγ by MAIT cell subsets was compared. Only a mean of 5% of 
CD4+ CD161++ Vα7.2+ T cells produced IFNγ (Figures S2D 
in Supplementary Material), compared to the high proportion 
of IFNγ+ CD8+ and DN CD161++ Vα7.2+ T  cells following 
IL-12  +  IL-18 stimulation. This was also confirmed using a 
LEGENDplex bead-based immunoassay of sorted CD161++ 
Vα7.2+ T cell subsets (Figures S2E,F in Supplementary Material).
Together, these results suggest that blood CD4+ CD161++ 
Vα7.2+ T cells have a low capacity to secrete Th1 cytokines com-
pared to other subsets of CD161++ Vα7.2+ T cells, and do not 
degranulate after short-term activation. Interestingly, within the 
liver, a greater proportion of all CD161++ Vα7.2+ T cell subsets 
expressed CD56 (Figure  4G). Intrahepatic CD8+ CD161++ 
Vα7.2+ T cells had the highest MR1-dependent IFNγ expression 
in response to E. coli-pulsed THP1 cells compared to DN and 
CD4+ CD161++ Vα7.2+ T cells (Figure 4H), and CD56 expres-
sion was associated with a higher frequency of IFNγ+ CD161++ 
Vα7.2+ T cells (Figure 4I). This was especially true within the 
intrahepatic CD4+ subset, suggesting that CD56 expression is 
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associated with a greater Th1 response from CD4+ CD161++ 
Vα7.2+ T cells.
Next, the potential of CD161++ Vα7.2+ T cells to produce Th2 
cytokines was investigated. PBMCs were cultured in Th2-skewing 
conditions (IL-4 +  IL-2) and restimulated with PMA/ionomycin 
for 5 h (Figure 4J). Blood CD4+ CD161++ Vα7.2+ T cells con-
tained a significantly higher fraction of cells expressing IL-4 and 
IL-13 compared to the CD8+ and DN CD161++ Vα7.2+ T cells 
(Figures 4K,L). In turn, CD4+ CD161++ Vα7.2+ T cells produced 
significantly less IFNγ compared to their CD8+ and DN counter-
parts in response to PMA/ionomycin (Figure 4M), in line with their 
reduced capacity to produce IFNγ in previous assays. Interestingly, 
low production of IL-4 and IL-13 was unique to CD161++ Vα7.2+ 
T cells within the CD8+ T cell population, as other populations 
within CD8+ T cells were able to produce IL-4 and IL-13 to similar 
or greater levels compared to CD4+ T  cells (Figures S2G–I in 
Supplementary Material). A similar trend was visible within the 
DN T cell population, whereas within the CD4+ T cell population, 
the ability of CD161++ Vα7.2+ T cells to produce IL-4 and IL-13 
was comparable to conventional CD4+ T  cell populations. This 
suggests that Th2 cytokine production may be uniquely suppressed 
within CD8+, and to a lesser extent, DN CD161++ Vα7.2+ T cells, 
compared to CD4+ CD161++ Vα7.2+ T cells.
Mr1-Tetramer-sorted cD161++ cD4+ 
MaiT cells have lower eomes and PlZF 
expression
Next, to confirm the MR1-reactivity of the cells, we used 
5-OP-RU-MR1-tetramers to define MAIT cells (Figures 5A–D). 
FigUre 3 | CD4+ CD161++ Vα7.2+ T cells have reduced Eomes expression and low cytotoxic potential. (a) The frequency of CD8+, double-negative (DN), and 
CD4+ CD161++ Vα7.2+ T cells expressing the indicated transcription factors (TFs). Bars indicate mean ± SEM, ****P < 0.0001, ***P < 0.001 by two-way repeated 
measures ANOVA with Dunnett’s multiple comparisons test, compared to CD8+ CD161++ Vα7.2+ cells. All other comparisons were not significant (n = 8; data 
pooled from two independent experiments). (B) Representative flow cytometry plots gated on total CD8+ (top row), DN (second row), CD4+ (third row) T cells 
showing expression of indicated TFs. Blue = CD161++ Vα7.2+ T cells; red = bulk T cells. (c) Overlaid histograms of cells gated on CD8+, CD4+, or DN CD161++ 
Vα7.2+ T cells showing the expression of the indicated TF, overlaid with their respective isotype control stains in gray as per legend. In all graphs, CD8+ cells are 
shown in red, DN cells in blue, and CD4+ cells in green. (D–g) Frequency of CD8+, DN, CD4+ CD161++ Vα7.2+ T cells expressing: (D) granzyme (Gr) A, (e) GrK, 
(F) granzyme B (GrB), or (g) perforin, showing mean ± SEM. ****P < 0.0001, **P < 0.01 by repeated measures one-way ANOVA with Bonferroni’s multiple 
comparisons test, compared to CD8+ CD161++ Vα7.2+ T cells (n = 10; data pooled from two independent experiments). (h,i) Upregulation of GrB and perforin in 
CD161++ Vα7.2+ T cell subsets following stimulation with Escherichia coli-treated THP1 cells for 24 h. (h) Representative staining showing GrB and perforin 
upregulation in CD161++ Vα7.2+ T cells. Percentages indicate frequency of cells expressing indicated effector molecule, based on isotype control. (i) The fraction 
of cells expressing GrB or perforin at resting conditions was subtracted to show increases in GrB or perforin expression after E. coli stimulation. ***P < 0.001 by 
repeated measures one-way ANOVA with Bonferroni’s multiple comparisons test, compared to CD8+ CD161++ Vα7.2+ T cells (n = 10; data pooled from two 
independent experiments). All other comparisons were non-significant.
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Although we had found that the Vα7.2-Jα33/12/20 gDNA 
rearrangement was 339-fold enriched in the CD4+ CD161++ 
Vα7.2+ T  cells compared to Vα7.2−CD161−T  cells (40), 
and was not significantly different to the abundance of 
the Vα7.2-Jα33/12/20 rearrangement in CD8+ CD161++ 
Vα7.2+ T  cells (Figure S3 in Supplementary Material), the 
MR1-tetramer has recently become widely available and is the 
most accurate method of defining MAIT cells. We found that 
the frequency of CD161++ MR1-tetramer+ cells that were 
CD8+ (76.9 ±  5.1%) was comparable with the frequency of 
CD8+ cells within CD161++ Vα7.2+ T  cells (76.7 ±  5%). 
DN CD161+ MR1-tetramer+ T  cells were similarly com-
parable with DN CD161++ Vα7.2+ T  cells (19.0 vs. 18.2%; 
Figures  5C,D). The frequency of CD161++ Vα7.2+ T  cells 
that were CD4+ (1.9 ±  0.5%), however, was slightly higher 
than the frequency of CD161++ MR1-tetramer+ T cells that 
were CD4+ (0.9 ± 0.3%) in the same donors. This suggests that 
a proportion of the CD4+ CD161++ Vα7.2+ T cells may be 
CD161++ CD4+ T cells that express the TCRα chain Vα7.2 
but have a different specificity.
In order to improve the staining and phenotype, the CD4+ 
MR1-tetramer+ cells, we sorted for MAIT  cells using MR1-
tetramer bead enrichment and investigated whether charac-
teristics of CD4+ CD161++ Vα7.2+ T cells were shared with 
CD4+ MR1-tetramer+ cells (Figure 6A). We focused on four 
phenotypic markers that were differentially expressed in CD4+ 
CD161++ Vα7.2+ T  cells compared to CD8+ and DN cells 
(summarized in Table  1). This analysis showed that in each 
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case, there was a significant difference between the frequency 
of marker expression in CD4+ CD161++ Vα7.2+ T  cells 
compared to sorted CD4+ MR1-tetramer+ T cells due to some 
of the CD4+ CD161++ Vα7.2+ T cell population being non-
MAIT, MR1-tetramer-negative cells (Figures 6C–F). However, 
we found that the frequency of Eomes+ cells as well as PLZF+ 
cells was significantly lower in CD4+ MR1-tetramer+ cells 
compared to CD8+ and DN MR1-tetramer+ cells, as found 
in CD4+ CD161++ Vα7.2+ T  cells (Figures  6B–D). A small 
proportion of CD4+ MR1-tetramer+ cells also expressed CCR4, 
similar to CD4+ CD161++ Vα7.2+ T cells, although at a lower 
frequency compared to the frequency of CCR4+ cells within 
CD4+ CD161++ Vα7.2+ T  cells and the expression was het-
erogeneous (Figure 6E). CCR7 expression, by contrast, was sig-
nificantly different between CD161++ Vα7.2+ T cell subsets but 
not between MR1-tetramer sorted cells (Figure 6F). Of note, in 
both CD161++ MR1-tetramer+ T cells and CD161++ Vα7.2+ 
T  cells, Eomes and PLZF were coexpressed, while Eomes and 
PLZF were expressed in a mutually exclusive manner with CCR4 
(Figure 6G). This suggests that although some CD4+ CD161++ 
Vα7.2+ T cells did not stain for the MR1-tetramer, the pattern of 
expression of Eomes, PLZF, and CCR4 is shared between CD4+ 
CD161++ Vα7.2+ T  cells and CD4+ MR1-tetramer+ cells. 
Further analysis of the coexpression of Eomes and PLZF with 
FigUre 4 | CD8+ and double-negative (DN) CD161++ Vα7.2+ T cells have a higher capacity to secrete T helper 1 cytokines. (a–F) THP1 cells were cultured with 
Escherichia coli overnight before co-culturing with peripheral blood mononuclear cells (PBMCs) for 5 h. (a) PBMCs were cultured for 5 h with E. coli-treated THP1 
cells in the presence or absence of anti-MHC class I-related protein 1 (MR1) blocking antibody. Representative staining is shown. (B) Frequency of CD161++ 
Vα7.2+ T cells expressing IFNγ (B) or interleukin-17 (IL-17) (c) in response to E. coli-treated THP1s in the presence or absence of indicated blocking antibodies 
against MR1, IL-12, IL-18, or isotype controls for 5 h. Bars indicate mean ± SEM (n = 5 for IFNγ, n = 10 for IL-17). ****P < 0.0001, **P < 0.01 by two-way ANOVA 
with Dunnett’s multiple comparisons test, compared to E. coli + isotype for each subset. Comparison with no E. coli not shown. (D–F) Frequency of CD8+, DN, or 
CD4+ CD161++ Vα7.2+ T cells expressing (D) IFNγ (e) TNFα (F) CD107a in response to E. coli-treated THP1s. ****P < 0.0001 by repeated measures one-way 
ANOVA with Dunnett’s multiple comparisons test, compared to CD8+ CD161++ Vα7.2+ T cells. All other comparisons were non-significant (n = 19 for IFNγ, from 
three independent experiments; n = 5 for all others). (g) Frequencies of CD56-expressing CD161++ Vα7.2+ T cells within blood and liver, according to coreceptor 
expression. ****P < 0.0001, ***P < 0.001, **P < 0.01 by two-way ANOVA with Dunnett’s multiple comparisons test, compared to adult blood within each subset. 
Other comparisons were non-significant. (h,i) Intrahepatic lymphocyte cells were cultured with E. coli-treated THP1 cells for 5 h. Representative staining (h) of 
IFNγ-expressing intrahepatic CD161++ Vα7.2+ T cells, in the presence or absence of an anti-MR1 blocking antibody added at 10 μg/ml: (blue line) or isotype 
control (red line). (i) Expression of IFNγ from indicated intrahepatic CD161++ Vα7.2+ T cell subsets according to CD56 expression. ****P < 0.0001, *P < 0.05 by 
two-way repeated measures ANOVA with Tukey’s multiple comparisons test, comparing CD56+ and CD56− cells within each CD161++ Vα7.2+ T cell subset 
(n = 3). (J–M) PBMCs were cultured in Th2-skewing conditions [interleukin-4 (IL-4) + IL-2, see Materials and Methods] and restimulated with phorbol 12-myristate 
13-acetate (PMA)/ionomycin for 5 h. (J) Representative plots showing IL-4, IL-13, and IFNγ production in response to PMA/ionomycin from CD161++ Vα7.2+ 
T cells. (K–M) Percentage of CD161++ Vα7.2+ T cells expressing (K) IL-4 (l) IL-13 (M) IFNγ. ****P < 0.0001, **P < 0.01 by repeated measures one-way ANOVA 
with Dunnett’s multiple comparisons test, compared to CD8+ CD161++ Vα7.2+ T cells (n = 11; data pooled from two independent experiments). All other 
comparisons were not significant.
11
Kurioka et al. Human CD161++ Vα7.2+ T Cell Subsets
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1031
the other markers differentially expressed between CD4+ and 
CD4−CD161++ Vα7.2+ T cells showed that CD56, Granzyme 
A and IFNγ expression is restricted to Eomes+ cells, particu-
larly within CD4+ CD161++ Vα7.2+ T cells (Figures S4A,B in 
Supplementary Material).
cD8 coreceptor Blockade reduces cD8+ 
MaiT cell activation by E. coli-Treated 
ThP1 cells
Thus far, no major differences could be observed between the 
CD8+ and DN MAIT/CD161++Vα7.2+ T  cells in pheno-
type and function in our model. Given that the ratio of DN 
MAIT cells to CD8+ MAIT cells has been reported to increase 
with age (15, 16), we asked whether there may be difference in 
survival after antigen-dependent activation. Therefore, PBMCs 
were added to E. coli-treated THP1 cells and expression of the 
apoptosis marker Annexin V on CD161++ Vα7.2+ T cells was 
assessed (Figure  7A). This in fact showed that the increase 
in Annexin V-expressing cells following stimulation was 
significantly greater in DN CD161++ Vα7.2+ T cells, compared 
to CD8+ cells (Figure 7B). Thus, although both CD8+ and DN 
CD161++ Vα7.2+ T  cells are similarly activated in an MR1-
dependent manner in our model, the CD8+ CD161++ Vα7.2+ 
T cell population may be protected from activation-induced cell 
death.
To further investigate the role of the CD8 coreceptor in the 
function of MAIT/CD161++ Vα7.2+ T  cells, PBMCs were 
incubated with E. coli-treated THP1 cells over 5 h in the presence 
or absence of an anti-CD8α blocking antibody (clone LT8). Due 
to the residual loss of CD8 staining from the presence of the anti-
CD8 antibody, CD4−CD161++ Vα7.2+ T cells were gated in the 
following experiments. We found a dose-dependent reduction in 
the frequency of IFNγ+ CD161++ Vα7.2+ T cells with CD8 core-
ceptor blockade, compared to the isotype control (Figures 7C,D). 
This effect was also seen when measuring different outputs of 
TCR signaling, namely TNFα, CD107a, and macrophage inflam-
matory protein-1β (Figures  7E–H). Interestingly, the degree 
to which CD8-coreceptor blockade affected the response of 
CD161++ Vα7.2+ T  cells differed depending on the response 
FigUre 5 | MHC class I-related protein 1 (MR1)-tetramer staining identifies mucosal-associated invariant T cells within the CD161++ Vα7.2+ T cell population. (a) 
Representative plots showing cells staining for 5-OP-RU MR1-tetramer (top) or Vα7.2 antibody (bottom) within CD4+, CD8+, and double-negative (DN) T cells. Cells 
are from the same donor, stained in parallel. Frequency of cells within CD4+, CD8+, or DN T cells shown in (B). **P < 0.01 or *P < 0.05, or non-significant = ns by 
repeated measures one-way ANOVA with Dunnett’s multiple comparisons test, compared to CD8+ T cells (n = 9). (c) Same cells as (a), showing coreceptor 
expression on CD161++ T cells stained with 5-OP-RU MR1-tetramer (top) or Vα7.2 antibody (bottom). (D) Coreceptor expression on CD161++ MR1-tetramer+ 
cells (top) and CD161++ Vα7.2+ T cells (bottom). ****P < 0.0001, ***P < 0.001 by repeated measures one-way ANOVA with Dunnett’s multiple comparisons test, 
compared to CD8+ T cells (n = 9).
12
Kurioka et al. Human CD161++ Vα7.2+ T Cell Subsets
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1031
measured, with the inhibitory effect of CD8 coreceptor blockade 
increasing as follows: MIP-1β < CD107a < TNFα ≤ IFNγ. When 
magnetically enriched CD8+ T  cells and the CD8-depleted 
population were cultured with E. coli-treated THP1s in the pres-
ence of the anti-CD8 blocking antibody, there was a significant 
reduction in the frequency of IFNγ+ and TNFα+ cells in the 
CD8+ CD161++ Vα7.2+ T cells but not in the DN CD161++ 
Vα7.2+ T cell population (Figure S5 in Supplementary Material), 
confirming the specificity of the anti-CD8 blocking antibody.
DiscUssiOn
In this study, we have performed a detailed comparison of the 
CD4+, CD8+, and DN CD161++ Vα7.2+ T cell subsets in paral-
lel, in terms of their phenotype, cytokine secretion, cytotoxicity, 
and TF expression, which has highlighted their distinct and 
overlapping characteristics.
First, we found that CD4+ CD161++ Vα7.2+ T cells have a 
lower frequency of cells expressing Eomes and PLZF compared 
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to their CD4− counterparts—a feature shared with CD4+ 
MR1-tetramer+ cells. Interestingly, there was a complete lack of 
degranulation by CD4+ CD161++ Vα7.2+ T cells in response 
to E. coli stimulation, while Eomes+ CD4+ CD161++ Vα7.2+ 
T cells were enriched for CD56+ and GrA+ cells (Figures S4B,C in 
Supplementary Material). Thus, CD4+ CD161++ Vα7.2+ T cells 
may have lower cytotoxic capacity compared to CD4− subsets 
due to their reduced expression of Eomes. In addition to their 
lower cytotoxic potential, CD4+ CD161++ Vα7.2+ T cells had 
a lower capacity to produce Th1 cytokines, and IFNγ expression 
from CD4+ CD161++ Vα7.2+ T cells was restricted to Eomes+ 
cells. The CD4+ subset of cells also had a higher capacity to 
secrete IL-4 and IL-13 compared to their CD4− counterparts, 
which is in line with the fact that overexpression of Runx3, the 
FigUre 6 | MHC class I-related protein 1 (MR1)-tetramer bead enrichment shows that CD161++ CD4+ mucosal-associated invariant T (MAIT) cells have lower 
Eomes and promyelocytic leukemia zinc finger (PLZF) expression. (a) Representative plots showing the enrichment of MAIT cells by magnetic bead enrichment 
using the MR1-tetramer. (B) Expression of PLZF, Eomes, and CCR4 on CD161++ MR1-tetramer+ cells according to coreceptor expression, before or after tetramer 
enrichment (n = 9). **P < 0.01, *P < 0.05 by repeated measures one-way ANOVA with Dunnett’s multiple comparisons test. Fluorescence-activated cell sorted plots 
show the expression of the indicated marker on cells gated on either CD161++ MR1-tetramer+ cells before or after tetramer enrichment from the same donor and 
gated on CD4+ (red) or CD8+ (blue) cells. Plots gated on CD161++ Vα7.2+ T cells shown for comparison. (c–F) Comparison of the frequency of cells expressing 
Eomes (c), PLZF (D), CCR4 (e), and CCR7 (F) within CD161++ Vα7.2+ T cells (black) and CD161++ MR1-tetramer+ cells within MR1-tetramer enriched cells 
(gray). ****P < 0.0001, **P < 0.01, *P < 0.05, and ns = non-significant by two-way ANOVA with Dunnett’s multiple comparisons test comparing each subset to CD8 
cells, or by two-way ANOVA with Sidak’s multiple comparisons test comparing Vα7.2+ cells with MR1-tetramer+ cells. (g) Coexpression of PLZF, Eomes, and 
CCR4 on cells gated on either CD161++ MR1-tetramer+ cells or CD161++ Vα7.2+ T cells, and then gated on CD4+ (red) or CD8+ (blue) cells.
TaBle 1 | Summary of markers that are significantly differentially expressed 
between CD4, CD8, and double-negative (DN) subsets of CD161++ Vα7.2+ 
T cells, or MR1-tetramer+ MAIT cells.
cD161++Vα7.2+ 
T cells
Mr1-tetramer+  
MaiT cells
Marker cD4 cD8 Dn cD4 cD8 Dn
CCR4 + − − + − −
CCR7 + − − − − −
PLZF ++ +++ +++ ++ +++ +++
Eomes + +++ +++ + +++ +++
PLZF, promyelocytic leukemia zinc finger; Eomes, eomesdermin; +++, high expression; 
++, medium expression; +, low expression; −, no expression.
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silencer of CD4 expression during T cell development, induces 
Eomes and suppresses IL-4 secretion (41). Although the propor-
tion of CD161++ Vα7.2+ T  cells secreting Th2 cytokines was 
generally low compared to Th1 cytokine-producing CD161++ 
Vα7.2+ T  cells, this supports recent findings in Vα19-Jα33 
TCR-transgenic mice showing that CD4+ MAIT cells were the 
dominant producers of IL-4 in response to TCR stimulation (42).
Interestingly, all subsets of intrahepatic CD161++ Vα7.2+ 
T cells expressed CD56 at high levels, which was associated with 
a higher effector function, especially in the CD4+ subset, secret-
ing abundant IFNγ in response to MR1-presented antigen. As 
CD56 expression has been previously associated with increased 
cytotoxic effector function of T cells (43, 44), CD4+ CD161++ 
Vα7.2+ T cells may also have heterogeneous cytotoxic capacities 
depending on the tissue they reside in. Increased CD56 expres-
sion in T cells and NK cells have been reported in in vitro cultures 
of cells with common γ-chain cytokines (43, 45). It is, therefore, 
possible that the intrahepatic cytokine milieu upregulates CD56 
expression on all MAIT cell subsets and lowers their activation 
threshold and/or skews them toward a Th1 response. Indeed, 
intrahepatic lymphocytes are dominated by rapidly acting innate 
cells, including MAIT  cells, γδ T  cells, NK  cells, and T  cells 
expressing NK receptors, e.g., CD56, and constitutive expression 
of cytokines, such as IL-15 (46) and IL-7 (30), may activate and 
induce CD56 upregulation in MAIT cells.
In addition, we found that all three CD161++ Vα7.2+ T cell 
subsets expressed ThPOK, the master regulator of the CD4 
lineage (47), at an intermediate level (ThPOKlow). Whether this 
TF may be expressed at a higher level in the CD4+ subset of 
CD161++ Vα7.2+ T cells during their development is unknown. 
Interestingly, a recent report showed that developing MAIT cells 
in the thymus transition from mostly CD4+ or CD4+ CD8+ 
to DN or CD8+ cells, which does not occur in PLZF-deficient 
mice (48). This suggests that the expression of coreceptors dur-
ing development may be determined by the maturation status of 
MAIT cells, rather than CD4/CD8 lineage commitment signals 
regulated by TFs such as ThPOK. Of note, ThPOK also negatively 
regulates Th17 differentiation and, thus, only cells that express low 
levels of ThPOK are permissive for the differentiation of type-17 
iNKT cells (20, 37, 49). As all subsets of CD161++ Vα7.2+ T cells 
expressed IL-17 to a similar level, CD161++ Vα7.2+ T cells may 
also express a reduced amount of ThPOK that is permissive for 
the expression of RORγt.
15
Kurioka et al. Human CD161++ Vα7.2+ T Cell Subsets
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1031
FigUre 7 | Continued
The most accurate method of defining a MAIT cell currently 
available is by identification of cells that bind the MR1-tetramer. 
The MR1-tetramer has been developed (4, 5) but was not 
widely available until recently, and so the most commonly used 
method for identifying MAIT cells has previously been to look at 
CD161++ Vα7.2+ T cells. These cells have been shown to overlap 
with CD161++ MR1-tetramer stained cells (4), particularly in 
CD8+ and DN cells (27). In this study, we show that although 
FigUre 7 | Continued  
CD8 coreceptor blockade reduces CD8+ CD161++ Vα7.2+ T cell activation by Escherichia coli-treated THP1 cells. (a) Representative flow cytometry plot of 
Annexin V staining of CD8+ (top) or double-negative (DN) (bottom) CD161++ Vα7.2+ T cells following incubation with E. coli-treated THP1 cells for 5 h. Total % of 
Annexin V+ cells after E. coli stimulation in indicated populations are shown. (B) Percentage increase in the frequency of Annexin V+ CD161++ Vα7.2+ T cells 
compared to unstimulated cells. **P < 0.01 by paired t-test (n = 11; data from two independent experiments). (c) Data from two independent experiments showing 
the frequency of CD4−CD161++ Vα7.2+ T cells expressing IFNγ in response to E. coli-treated THP1s in the presence or absence of blocking antibodies against 
CD8 (5 µg/ml), or isotype control for 5 h (n = 9). Data are presented as relative IFNγ expression compared with that of co-cultures in the absence of any antibodies. 
**P < 0.01 by one-way ANOVA with Dunnett’s multiple comparisons test, compared to CD161++ Vα7.2+ T cells cultured in the absence of any antibodies. (D) 
Representative plots of IFNγ expression in CD4− CD161++ Vα7.2+ T cells cultured in the presence of increasing concentrations of blocking antibody against CD8, 
or isotype control, or in the absence of antibodies (far left column). (e–h) Frequency of CD4− CD161++ Vα7.2+ T cells expressing (e) IFNγ, (F) TNFα, (g) CD107a, 
or (h) macrophage inflammatory protein-1β (MIP-1β) in the presence (red) or absence (blue) of a blocking antibody against CD8. Each symbol and bar represents 
the mean ± SEM (n = 5). ****P < 0.0001, ***P < 0.001, *P < 0.05 by two-way repeated measures ANOVA with Dunnett’s multiple comparisons test, compared to 
CD161++ Vα7.2+ T cells cultured at the corresponding concentration of isotype control antibody. All other comparisons were non-significant.
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the MAIT  cell TCR Vα7.2-Jα33/12/20 is enriched within the 
CD4+ CD161++ Vα7.2+ T  cell population, not all CD4+ 
CD161++ Vα7.2+ T  cells could be detected by the 5-OP-RU-
loaded MR1-tetramer. This suggests that some CD4+ CD161++ 
Vα7.2+ T cells may be conventional T cells expressing the Vα7.2 
chain, consistent with a previous report (50). This heterogeneity 
of the CD4+ CD161++ Vα7.2+ T cell population can explain 
some of the differences observed between CD4+ and CD8+/DN 
CD161++ Vα7.2+ T cell populations, as the latter subsets mostly 
overlap with CD161++ MR1-tetramer+ cells. This shows that 
particularly when looking at CD4 populations, the MR1-tetramer 
should be used to accurately identify MAIT cells. Thus, when we 
compared the phenotypic differences between CD161++ Vα7.2+ 
T  cell subsets with MR1-tetramer defined MAIT  cell subsets, 
there was a significant difference between the level of marker 
expression in CD4+ CD161++ Vα7.2+ cells and CD4+ MR1-
tetramer+ cells. Interestingly, however, CD4+ MR1-tetramer+ 
cells sorted using the MR1-tetramer were found to have signifi-
cantly lower levels of Eomes and PLZF, and a significantly higher 
level of CCR4 compared to their CD4− counterparts, as found 
in CD161++ Vα7.2+ T cell subsets. The pattern of coexpression 
of these markers was also found to be similar between CD4+ 
MR1-tetramer+ cells and CD4+ CD161++ Vα7.2+ T cells. Thus, 
although there is less heterogeneity between MAIT cell subsets as 
defined by MR1-tetramers compared to CD161++ Vα7.2+ T cell 
subsets, the CD4 subset seems to be inherently more heterogene-
ous compared to the CD8/DN MAIT cell subset. Nevertheless, 
it will be important for future studies to further confirm any 
differences between MAIT cell subsets using the MR1-tetramer.
CD8+ and DN CD161++ Vα7.2+ T cells were functionally 
and phenotypically similar in this study and largely overlapped 
with 5-OP-RU-loaded MR1-tetramer stained cells. Thus, 
whether the CD8 coreceptor may affect the activation of CD8+ 
CD161++ Vα7.2+/MAIT cells was investigated. Although CD8α 
was not necessary for the activation of MAIT cells in our model, 
CD8+ MAIT cell responses were reduced in a dose-dependent 
manner by the addition of an anti-CD8α blocking antibody. As 
the structure and residues of the CD8-binding domain of MHC 
class I is conserved between MR1 and MHC class I molecules, it 
has been suggested that MR1 may bind CD8αα (4, 33). It is well 
attested that the binding of CD8 to MHC class I stabilizes the 
TCR/peptide–MHC class I interaction (51), and the results here 
support the idea that the CD8 coreceptor similarly stabilizes 
the MAIT TCR/MR1 interaction. We found that there was a 
hierarchy in cellular responses of MAIT cells that are affected by 
CD8 coreceptor blockade—the order was as follows, from least 
affected to most affected: MIP-1β < CD107a < TNFα ≤ IFNγ. 
This series is similar to the hierarchy in cellular responses elicited 
by peptide–MHC class I stimulation (52). Interestingly, studies 
using other activation models, such as Helicobacter pylori, have 
found a higher capacity of CD8+ MAIT cells to secrete cytokines 
and degranulate, suggesting that the CD8 coreceptor may play a 
more significant role in MR1-dependent activation in response 
to certain pathogens, or in response to low doses of antigen (53). 
Importantly, however, we cannot rule out that, in our assays, 
CD8 is acting as a simple adhesion molecule, or that the antibody 
is hindering the interaction between MR1 and the MAIT  cell 
TCR. Furthermore, the CD8 coreceptor blockade may only be 
modifying the activation of CD8αβ+ MAIT cells. This is because 
the CD8β chain is required for efficient coreceptor function (54). 
A large fraction of the CD8+ MAIT  cells express the CD8αα 
homodyne, which sequesters p56lck away from the TCR due to 
its exclusion from lipid rafts and, therefore, are thought to be 
inhibitory (55, 56). In order to confirm the function of the CD8 
coreceptor on MAIT cell activation, further studies disrupting 
the potential CD8-binding site of MR1 will be necessary (57).
In conclusion, we have explored the heterogeneous as well 
as homogeneous phenotypes and functions of the three defined 
subsets of CD161++ Vα7.2+ T cells. Differences in TF expres-
sion, chemokine receptor expression, and capacity to secrete Th1 
cytokines support the notion that different CD161++ Vα7.2+ 
T cell subsets, and the MAIT cells contained within this popula-
tion, may play distinct roles in health and disease, and future 
studies will be warranted to further investigate the development 
and function of these cells.
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